CD News | American Association for Cancer Research
MyProstateScore 2.0 (MPS2) proved more accurate at detecting prostate cancer than PSA and other biomarkers, researchers reported, sparing men more invasive testing, such as prostate biopsies and MRI (JAMA Oncol 2024 Apr 18). The test was designed to specifically identify higher-grade disease by measuring expression of 18 genes most often found in the presence of significant cancers. In 743 men with elevated PSA levels, using MPS2 would have avoided 35% to 42% of prostate biopsies without missing diagnoses